JP2013533875A5 - - Google Patents

Info

Publication number

JP2013533875A5

JP2013533875A5 JP2013518254A JP2013518254A JP2013533875A5 JP 2013533875 A5 JP2013533875 A5 JP 2013533875A5 JP 2013518254 A JP2013518254 A JP 2013518254A JP 2013518254 A JP2013518254 A JP 2013518254A JP 2013533875 A5 JP2013533875 A5 JP 2013533875A5

Authority

JP

Japan

Prior art keywords

facviia

immunoglobulin

region

facvii

conjugate according

Prior art date

2011-06-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108060003951 Immunoglobulin Proteins 0.000 claims 21
• 102000018358 immunoglobulin Human genes 0.000 claims 21
• 229920000642 polymer Polymers 0.000 claims 20
• 238000004519 manufacturing process Methods 0.000 claims 8
• 108090000765 processed proteins & peptides Proteins 0.000 claims 7
• 230000023555 blood coagulation Effects 0.000 claims 4
• 239000002202 Polyethylene glycol Substances 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 3
• 125000003172 aldehyde group Chemical group 0.000 claims 3
• 150000001299 aldehydes Chemical class 0.000 claims 3
• 201000010099 disease Diseases 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 229920001223 polyethylene glycol Polymers 0.000 claims 3
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
• 230000003213 activating effect Effects 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 239000011541 reaction mixture Substances 0.000 claims 2
• -1 succinimidyl carboxymethyl Chemical group 0.000 claims 2
• ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 claims 1
• AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical group CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 claims 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
• 229920002101 Chitin Polymers 0.000 claims 1
• 229920002307 Dextran Polymers 0.000 claims 1
• 208000031220 Hemophilia Diseases 0.000 claims 1
• 208000009292 Hemophilia A Diseases 0.000 claims 1
• 208000032843 Hemorrhage Diseases 0.000 claims 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
• 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 1
• 230000001154 acute effect Effects 0.000 claims 1
• 125000003277 amino group Chemical group 0.000 claims 1
• 229920002988 biodegradable polymer Polymers 0.000 claims 1
• 239000004621 biodegradable polymer Substances 0.000 claims 1
• 208000034158 bleeding Diseases 0.000 claims 1
• 230000000740 bleeding effect Effects 0.000 claims 1
• 229920001577 copolymer Polymers 0.000 claims 1
• 230000007812 deficiency Effects 0.000 claims 1
• 239000000539 dimer Substances 0.000 claims 1
• 150000004676 glycans Chemical class 0.000 claims 1
• 229920002674 hyaluronan Polymers 0.000 claims 1
• 229960003160 hyaluronic acid Drugs 0.000 claims 1
• 208000014674 injury Diseases 0.000 claims 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
• 150000002632 lipids Chemical class 0.000 claims 1
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
• 229920001451 polypropylene glycol Polymers 0.000 claims 1
• 229920001282 polysaccharide Polymers 0.000 claims 1
• 239000005017 polysaccharide Substances 0.000 claims 1
• 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
• 229940124597 therapeutic agent Drugs 0.000 claims 1
• 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
• 230000008733 trauma Effects 0.000 claims 1
• 229920002554 vinyl polymer Polymers 0.000 claims 1